BerGenBio (OB:BGBIO) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

BGBIO 주식 개요

임상 단계의 바이오 제약 회사인 BerGenBio ASA는 노르웨이에서 약물 내성, 전이성 암, 호흡기 질환을 치료하는 의약품을 개발하는 회사입니다.

BGBIO 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	2/6
과거 실적	0/6
재무 상태	5/6
배당금	0/6

보상

수익은 연간 80.21% 증가할 것으로 예상됩니다.

위험 분석

cash runway 경력이 1년 미만입니다.

수익은 향후 3년간 연평균 24.9% 씩 감소할 것으로 예상됩니다.

수익이 1백만 달러 미만인 경우 ( NOK521K )

의미 있는 시가총액이 없습니다. ( NOK422M )

+ 3 더 많은 위험

BerGenBio ASA 경쟁사

Thor Medical

OB:TRMED

NOK 357.0m

Arctic Bioscience

OB:ABS

NOK 329.8m

Nordic Nanovector

OB:NANOV

NOK 231.8m

Lytix Biopharma

OB:LYTIX

NOK 303.6m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 BerGenBio
과거 주가
현재 주가	NOK 10.11
52주 최고치	NOK 35.80
52주 최저치	NOK 8.50
베타	1.61
11개월 변경	-7.25%
3개월 변경 사항	-10.99%
1년 변경 사항	-14.32%
33년 변화	-99.50%
5년 변화	-99.32%
IPO 이후 변화	-99.60%

최근 뉴스 및 업데이트

Recent updates

Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

Sep 21

Companies Like BerGenBio (OB:BGBIO) Could Be Quite Risky

Jun 02

Here's Why BerGenBio (OB:BGBIO) Must Use Its Cash Wisely

Dec 07

BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

Aug 24

BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

Feb 06

Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

Sep 26

Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

Jun 11

Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

Feb 17

We're Not Very Worried About BerGenBio's (OB:BGBIO) Cash Burn Rate

Sep 21

It's Unlikely That The CEO Of BerGenBio ASA (OB:BGBIO) Will See A Huge Pay Rise This Year

Mar 13

We're Interested To See How BerGenBio (OB:BGBIO) Uses Its Cash Hoard To Grow

Feb 11

What Kind Of Investors Own Most Of BerGenBio ASA (OB:BGBIO)?

Dec 21

주주 수익률

	BGBIO	NO Biotechs	NO 마켓
7D	1.2%	-2.4%	0.1%
1Y	-14.3%	-61.1%	1.2%

수익률 대 산업: BGBIO 지난 1년 동안 -53 %를 반환한 Norwegian Biotechs 산업을 초과했습니다.

수익률 대 시장: BGBIO 지난 1년 동안 0.4 %를 반환한 Norwegian 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is BGBIO's price volatile compared to industry and market?
BGBIO volatility
BGBIO Average Weekly Movement	8.8%
Biotechs Industry Average Movement	10.6%
Market Average Movement	5.0%
10% most volatile stocks in NO Market	11.4%
10% least volatile stocks in NO Market	2.8%

안정적인 주가: BGBIO 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: BGBIO 의 주간 변동성은 지난 1년 동안 19% 에서 10% 로 감소했지만 여전히 Norwegian 주식의 75%보다 높습니다.

회사 소개

설립	직원	CEO	웹사이트
2007	15	Martin Olin	www.bergenbio.com

임상 단계의 바이오 제약 회사인 BerGenBio ASA는 노르웨이에서 약물 내성, 전이성 암 및 호흡기 질환을 치료하는 의약품을 개발하는 회사입니다. 이 회사의 주요 임상 자산은 비소세포폐암 치료를 위해 임상 1b/2a상을 진행 중인 AXL 수용체 티로신 키나제(AXL) 억제제인 벰센티닙(BGB016)과 2차 비소세포폐암(2L NSCLC) 치료를 위해 임상 2상을 진행 중인 (BGBC008)입니다. 급성호흡곤란증후군 치료제로 전임상 중인 벰센티닙, 난소암 치료제로 임상 1상 중인 항AXL 단일클론항체 틸베스타맙(BGB149), 고형암 치료제로 임상 1상 중인 미파세타맙 우조티린을 개발 중입니다.

BerGenBio ASA 기본 사항 요약

BerGenBio 의 수익과 매출은 시가총액과 어떻게 비교하나요?
BGBIO 기본 통계
시가총액	NOK 395.17m
수익(TTM)	-NOK 155.40m
수익(TTM)	NOK 521.00k

758.5x

P/S 비율

-2.5x

P/E 비율

BGBIO 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
BGBIO 손익 계산서(TTM)
수익	NOK 521.00k
수익 비용	NOK 0
총 이익	NOK 521.00k
기타 비용	NOK 155.93m
수익	-NOK 155.40m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

Nov 13, 2024

주당 순이익(EPS)	-3.98
총 마진	100.00%
순이익 마진	-29,828.22%
부채/자본 비율	0%

BGBIO 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

BGBIO 주식 개요

보상

위험 분석

BerGenBio ASA 경쟁사

OB:TRMED

NOK 357.0m

OB:ABS

NOK 329.8m

OB:NANOV

NOK 231.8m

OB:LYTIX

NOK 303.6m

가격 내역 및 성능

최근 뉴스 및 업데이트

Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

Companies Like BerGenBio (OB:BGBIO) Could Be Quite Risky

BerGenBio ASA Announces Closure of EU-Solidact Bemcentinib Study Arm in Hospitalized COVID-19 Patients

BerGenBio ASA Announces Final Bemcentinib Phase 2 Data in AML and MDS Presented at the 2023 ASH Meeting

BerGenBio ASA has completed a Follow-on Equity Offering in the amount of €240.87 million.

Here's Why BerGenBio (OB:BGBIO) Must Use Its Cash Wisely

Recent updates

Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

Companies Like BerGenBio (OB:BGBIO) Could Be Quite Risky

BerGenBio ASA Announces Closure of EU-Solidact Bemcentinib Study Arm in Hospitalized COVID-19 Patients

BerGenBio ASA Announces Final Bemcentinib Phase 2 Data in AML and MDS Presented at the 2023 ASH Meeting

BerGenBio ASA has completed a Follow-on Equity Offering in the amount of €240.87 million.

Here's Why BerGenBio (OB:BGBIO) Must Use Its Cash Wisely

New major risk - Financial position

BerGenBio ASA to Report Q4, 2024 Results on Feb 19, 2025

BerGenBio ASA Announces Full Results of its Phase 2 BGBC008 Study of Bemcentinib and Pembrolizumab in Second Line Non-Small Cell Lung Cancer

BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

Price target decreased by 63% to kr5.68

New major risk - Shareholder dilution

BerGenBio ASA has completed a Follow-on Equity Offering in the amount of NOK 250 million.

Chief Executive Officer exercised options to buy kr323k worth of stock.

BerGenBio Announces Data from Bemcentinib Trial in Mesothelioma Presented at ASCO

BerGenBio ASA Announces Resignation of Francois Thomas from the Board of Directors

BerGenBio ASA to Report Q1, 2023 Results on Jun 22, 2023

High number of new and inexperienced directors

BerGenBio ASA Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients

BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

BerGenBio ASA Announces Board Appointments

BerGenBio ASA to Report Q3, 2023 Results on Nov 14, 2023

Price target decreased to kr12.00

BerGenBio ASA Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations

BerGenBio ASA Announces First Patient Randomized in Bemcentinib Trial in Eu-Solidact Platform for Hospitalized Covid-19 Patients

Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

BerGenBio ASA Provides Update on Clinical Development

Chairman of the Board recently bought kr268k worth of stock

Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

Consensus forecasts updated

Price target decreased to kr47.50

BerGenBio ASA Announces Complete Data Analysis of Accord2 Phase II Bemcentinib Study in Hospitalized Covid-19 Patients - Primary Efficacy Endpoint Met

Bergenbio Presents Bemcentinib Covid-19 Clinical Trial Data At Eccmid 2022

BerGenBio ASA Appoints Cristina Oliva as Chief Medical Officer, Effective April 25, 2022

Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

High number of new and inexperienced directors

Chief Executive Officer recently bought kr204k worth of stock

We're Not Very Worried About BerGenBio's (OB:BGBIO) Cash Burn Rate

BerGenBio ASA Completes Recruitment of Phase II AML Study ((BGBC003)

Chief Executive Officer Richard Godfrey has left the company

BerGenBio ASA Presents Encouraging Combined Data for Bemcentinib from Two Phase II Covid-19 Studies At Eccmid

BerGenBio ASA Updates Preliminary Survival Data from the Ongoing Phase II Study of Bemcentinib

BerGenBio ASA Receives Food and Drug Administration Fast Track Designation for Bemcentinib / Anti-Pd-(L)1 Combination in NSCLC

BerGenBio ASAPresents Data from Phase I/II Bemcentinib/Erlotinib Combination Trial in NSCLC

BerGenBio ASA to Present Data from Phase I/II Bemcentinib/Erlotinib Combination Trial in NSCLC at ASCO Meeting

BerGenBio ASA Announces Top Line Data from Phase II Trial Assessing Bemcentinib in Hospitalised Covid-19 Patients

BerGenBio ASA Announces Pre-Clinical COVID-19 Data Presented at Virtual Immunology 2021

It's Unlikely That The CEO Of BerGenBio ASA (OB:BGBIO) Will See A Huge Pay Rise This Year

BerGenBio ASA Completes Enrolment into Latest Cohort of Phase II Bemcentinib Combination Study in Refractory NSCLC

BerGenBio ASA Announces Start of Phase 1B Trial of Anti-AXL Antibody Tilvestamab (BGB149)

BerGenBio ASA Closes Recruitment into Trial Assessing Bemcentinib in Covid-19 Patients

New 90-day low: kr30.75

Analysts update estimates

We're Interested To See How BerGenBio (OB:BGBIO) Uses Its Cash Hoard To Grow

Revenue and earnings in line with expectations

BerGenBio ASA Announces Second Data Monitoring Committee Recommends Continuation of Bergenbio's BGBC020 Trial Assessing Bemcentinib in COVID-19 Patients

Price target raised to kr63.00

BerGenBio ASA Presents an Update from Its Phase II Study of Bemcentinib in Combination with Anti-PD-1 Therapy Pembrolizumab (Bgbc008)

Bergenbio to Present Updates from Ongoing Phase II Bemcentinib Combination Study in Refractory NSCLC At WCLC 2020